Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients

AIDS

Volumn 13, Issue 12, 1999, Pages 1485-1489

  Fätkenheuer, Gerd ^a   Hoetelmans, Richard M W ^b   Hunn, Nanni ^a   Schwenk, Achim ^a   Franzen, Caspar ^a   Reiser, Marcel ^a   Jütte, Alexander ^a   Rockstroh, Jürgen ^c   Diehl, Volker ^a   Salzberger, Bernd ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

AIDS; Drug monitoring; HIV; Plasma concentrations; Protease inhibitors; Ritonavir; Salvage therapy; Saquinavir; Virological failure

Indexed keywords

CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; LIPID; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MALE; METABOLIC DISORDER; PARESTHESIA; PRIORITY JOURNAL; SALVAGE THERAPY; SCHOOL CHILD;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SALVAGE THERAPY; SAQUINAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0032842750     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199908200-00007     Document Type: Article

References (25)

1. Deeks S, Loftus R, Cohen P, Chin S, Grant R, Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997 [Abstract LB-2].
2. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
3. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
4. DHHS. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Ann Intern Med 1998, 128:1079-1100.
5. Hoetelmans RM, van Essenberg M, Meenhorst PL, Mulder JW, Beijnen JH. Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1997, 698:235-241.
6. Hoetelmans RM, van Essenberg M, Profijl M, Meenhorst PL, Mulder JW, Beijnen JH. High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva. J Chromatogr B Biomed Sci Appl 1998, 705:119-126.
7. Cameron DW, Japour A, Mellors, et al. Antiretroviral safety & durability of ritonavir (RIT)-saquinavir (SQV) in protease inhibitor-naive patients in year two of follow-up. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, 1998 [Abstract 388].
8. Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998, 12:619-624.
9. Kaufmann GR, Duncombe C, Cunningham P, et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV- 1-infected individuals. AIDS 1998, 12:1625-1630.
10. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study. AIDS 1997, 11:F95-F99.
11. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998, 12:F97-F102.
12. Ruane PJ, Tam JT, Libraty DH, Sokolov RT, Uman SJ, Zakowski PC. Salvage theapy using ritonavir/saquinavir with a non-nucleoside reverse transcriptase inhibitor after prolonged failure with indinavir or ritonavir. 12th World AIDS Conference. Geneva, 1998 [Abstract 32308].
13. Hammer S, Squires K, Degruttola V, et al. Randomized trial of abacavir (ABC) & nelfinavir (NFV) in combination with efavirenz (EFV) and adefovir dipivoxil (ADV) as salvage therapy in patients with virologic failure receiving indinavir (IDV). 6th Conference on Retroviruses and Opportunistic Infections. Chicago, 1999 [Abstract 490].
14. Eron J, Falloon J, Masur H, et al. Activity of combination abacavir/amprenavir/efavirenz therapy in HIV1-infected subjects failing their current protease inhibitor containing regimen. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, 1998 [Abstract S13].
15. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997, 41:654-660.
16. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
17. Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection, Drugs 1996, 52:93-112.
18. Staszewski S, Gute P, Carlebach A, et al. Virological and immunological response to mega-HAART-salvage therapy after failure of multiple antiretroviral regimen, 4th International Congress on Drug Therapy in HIV Infection. Glasgow, 1998 [Abstract S40].
19. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:15341539.
20. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group, N Engl J Med 1995, 333:1528-1533.
21. Arribas JR, Ibánez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment [letter]. AIDS 1998, 12:1722-1724.
22. Duong M, Sgro C, Grappin M, Biron F, Boibieux A. Renal failure after treatment with ritonavir [letter]. Lancet 1996, 348:693.
23. Witzke O, Plentz A, Schäfers RF, Reinhardt W, Heemann U, Philipp T. Side-effects of ritonavir and its combination with saquinavir with special regard to renal function [letter]. AIDS 1997, 11:836-838.
24. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.
25. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.